Role of glutaminyl-peptide cyclotransferase in breast cancer doxorubicin sensitivity

References

• Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA-Cancer J Clin. 2021;71(3):209–13. doi:10.3322/caac.21660.
   PubMed Web of Science ®Google Scholar
• Miller KD, Nogueira L, Mariotto AB, Rowland JH, Yabroff KR, Alfano CM, Jemal A, Kramer JL, Siegel RL. Cancer treatment and survivorship statistics, 2019. CA-Cancer J Clin. 2019;69(5):363–385. doi:10.3322/caac.21565.
   PubMed Web of Science ®Google Scholar
• Sommer AK, Hermawan A, Ljepoja B, Fröhlich T, Arnold GJ, Wagner E, Roidl A. A proteomic analysis of chemoresistance development via sequential treatment with doxorubicin reveals novel players in MCF-7 breast cancer cells. Int J Mol Med. 2018;42(4):1987–1997. doi:10.3892/ijmm.2018.3781.
   PubMed Web of Science ®Google Scholar
• Mustafa YF, Mohammed NA. A promising oral 5-fluorouracil prodrug for lung tumor: synthesis, characterization and release. Biochem Cell Arch. 2021;21:1991–1999.
   Google Scholar
• Su ZZ, Kang DC, Chen Y, Pekarskaya O, Chao W, Volsky DJ, Fisher PB. Identification and cloning of human astrocyte genes displaying elevated expression after infection with HIV-1 or exposure to HIV-1 envelope glycoprotein by rapid subtraction hybridization. Oncogene. 2002;21(22):3592–3602. doi:10.1038/sj.onc.1205445.
   PubMed Web of Science ®Google Scholar
• Yang L, Tian Y, Leong WS, Song H, Yang W, Wang M, Wang X, Kong J, Shan B, Song Z. Efficient and tumor-specific knockdown of MTDH gene attenuates paclitaxel resistance of breast cancer cells both in vivo and in vitro. Breast Cancer Res. 2018;20(1):113. doi:10.1186/s13058-018-1042-7.
   PubMedGoogle Scholar
• Zhu K, Peng Y, Hu J, Zhan H, Yang L, Gao Q, Jia H, Luo R, Dai Z, Tang Z, et al. Metadherin–PRMT5 complex enhances the metastasis of hepatocellular carcinoma through the WNT–β-catenin signaling pathway. Carcinogenesis. 2020;41(2):130–138. doi:10.1093/carcin/bgz065.
   PubMed Web of Science ®Google Scholar
• Liu DC, Song LL, Li XZ, Liang Q, Zhang ZG, Han CH. Circular RNA circHIPK3 modulates prostate cancer progression via targeting miR-448/MTDH signaling. Clin Transl Oncol. 2021;23(12):2497–2506. doi:10.1007/s12094-021-02650-5.
   PubMed Web of Science ®Google Scholar
• Fu J, Peng J, Tu G. Knockdown MTDH inhibits glioma proliferation and migration and promotes apoptosis by downregulating MYBL2. Mediat Inflamm. 2022. 2022:1706787. doi:10.1155/2022/1706787.
   PubMed Web of Science ®Google Scholar
• Jiao Y, Yang H, Qian J, Gong Y, Liu H, Wu S, Cao L, Tang L. miR-3664‑5P suppresses the proliferation and metastasis of gastric cancer by attenuating the NF‑κB signaling pathway through targeting MTDH. Int J Oncol. 2019;54(3):845–858. doi:10.3892/ijo.2019.4680.
   PubMed Web of Science ®Google Scholar
• Manna D, Sarkar D. Multifunctional role of astrocyte elevated gene-1 (AEG-1) in cancer: focus on drug resistance. Cancers (Basel). 2021;13(8):1792. doi:10.3390/cancers13081792.
   PubMed Web of Science ®Google Scholar
• Song Z, Wang Y, Li C, Zhang D, Wang X. Molecular Modification of Metadherin/MTDH Impacts the Sensitivity of Breast Cancer to Doxorubicin. PloS One. 2015;10(5):e0127599. doi:10.1371/journal.pone.0127599.
   PubMed Web of Science ®Google Scholar
• Tang D, Ma J, Chu Z, Wang X, Zhao W, Zhang Q. Zhang Q apatinib-induced NF-κB inactivation sensitizes triple-negative breast cancer cells to doxorubicin. Am J Transl Res. 2020;12(7):3741–3753.
   PubMed Web of Science ®Google Scholar
• Kehlen A, Haegele M, Menge K, Gans K, Immel UD, Hoang-Vu C, Klonisch T, Demuth HU. Role of glutaminyl cyclases in thyroid carcinomas. Endocr Relat Cancer. 2013;20(1):79–90. doi:10.1530/ERC-12-0053.
   PubMed Web of Science ®Google Scholar
• Busby WH, Quackenbush GE, Humm J, Youngblood WW, Kizer JS. An enzyme(s) that converts glutaminyl-peptides into pyroglutamyl-peptides. Presence in pituitary, brain, adrenal medulla, and lymphocytes. J Biol Chem. 1987;262(18):8532–8536. doi:10.1016/S0021-9258(18)47446-7.
   PubMed Web of Science ®Google Scholar
• Coimbra JR, Sobral PJ, Santos AE, Moreira PI, Salvador JA. An overview of glutaminyl cyclase inhibitors for Alzheimer’s disease. Future Med Chem. 2019;11(24):3179–3194. doi:10.4155/fmc-2019-0163.
   PubMed Web of Science ®Google Scholar
• Vijayan DK, Zhang KYJ. Human glutaminyl cyclase: structure, function, inhibitors and involvement in Alzheimer’s disease. Pharmacol Res. 2019. 147:104342. doi:10.1016/j.phrs.2019.104342.
   PubMed Web of Science ®Google Scholar
• Zhao T, Bao Y, Gan X, Wang J, Chen Q, Dai Z, Liu B, Wang A, Sun S, Yang F, et al. DNA methylation-regulated QPCT promotes sunitinib resistance by increasing HRAS stability in renal cell carcinoma. Theranostics. 2019;9(21):6175–6190. doi:10.7150/thno.35572.
   PubMed Web of Science ®Google Scholar
• Zhao T, Zhou Y, Wang Q, Wang J, Chen Q, Dai Z, Liu B, Wang A, Sun S, Yang F, et al. QPCT regulation by CTCF leads to sunitinib resistance in renal cell carcinoma by promoting angiogenesis. Int J Oncol. 2021;59(1):48. doi:10.3892/ijo.2021.5228.
   PubMed Web of Science ®Google Scholar
• Shen M, Wei Y, Kim H, Wan L, Jiang YZ, Hang X, Raba M, Remiszewski S, Rowicki M, Wu CG, et al. Small-molecule inhibitors that disrupt the MTDH–SND1 complex suppress breast cancer progression and metastasis. Nat Cancer. 2022;3(1):43–59. doi:10.1038/s43018-021-00279-5.
   PubMedGoogle Scholar
• Tokunaga E, Nakashima Y, Yamashita N, Hisamatsu Y, Okada S, Akiyoshi S, Aishima S, Kitao H, Morita M, Maehara Y. Overexpression of metadherin/MTDH is associated with an aggressive phenotype and a poor prognosis in invasive breast cancer. Breast Cancer-Tokyo. 2014;21(3):341–349. doi:10.1007/s12282-012-0398-2.
   PubMed Web of Science ®Google Scholar
• Fang J, Zhu H, Xu P, Jiang R. Zingerone suppresses proliferation, invasion, and migration of hepatocellular carcinoma cells by the inhibition of MTDH-mediated PI3K/Akt pathway. J Recept Signal Transduct Res. 2022;42(4):409–417. doi:10.1080/10799893.2021.1988970.
   PubMed Web of Science ®Google Scholar
• Pei G, Luo M, Ni X, Wu J, Wang S, Ma Y, Yu J. Autophagy facilitates metadherin-induced chemotherapy resistance through the AMPK/ATG5 pathway in gastric cancer. Cell Physiol Biochem. 2018;46(2):847–859. doi:10.1159/000488742.
   PubMedGoogle Scholar
• Zhu K, Peng Y, Hu J, Zhan H, Yang L, Gao Q, Jia H, Luo R, Dai Z, Tang Z, et al. Metadherin-PRMT5 complex enhances the metastasis of hepatocellular carcinoma through the WNT-β-catenin signaling pathway. Carcinogenesis. 2020;41(2):130–138. doi:10.1093/carcin/bgz065.
   PubMed Web of Science ®Google Scholar
• Han C, Fu Y, Zeng N, Yin J, Li Q. LncRNA FAM83H-AS1 promotes triple-negative breast cancer progression by regulating the miR-136-5p/metadherin axis. Aging (Albany NY). 2020;12(4):3594–3616. doi:10.18632/aging.102832.
   PubMedGoogle Scholar
• Cai Y, Zhao X, Chen D, Zhang F, Chen Q, Shao CC, Ouyang YX, Feng J, Cui L, Chen M, et al. Circ-NOL10 regulated by MTDH/CASC3 inhibits breast cancer progression and metastasis via multiple miRnas and PDCD4. Mol Ther Nucleic Acids. 2021;26:773–786. doi:10.1016/j.omtn.2021.09.013.
   PubMedGoogle Scholar
• Wang Y, Dong L, Wan F, Chen F, Liu D, Chen D, Long J. MiR-9-3p regulates the biological functions and drug resistance of gemcitabine-treated breast cancer cells and affects tumor growth through targeting MTDH. Cell Death Disease. 2021;12(10):861. doi:10.1038/s41419-021-04145-1.
   PubMed Web of Science ®Google Scholar
• Liang Y, Hu J, Li J, Liu Y, Yu J, Zhuang X, Mu L, Kong X, Hong D, Yang Q, et al. Epigenetic activation of TWIST1 by MTDH promotes cancer stem–like cell traits in breast cancer. Cancer Research. 2015;75(17):3672–3680. doi:10.1158/0008-5472.CAN-15-0930.
   PubMed Web of Science ®Google Scholar
• Yuan L, Shi RR, Rao SM, Song JL, Cui MC. Reversal of resistance to adriamycin in human breast cancer cell line MCF-7/ADM by silencing AEG-1 gene and its mechanism. Sheng Li Xue Bao. 2014;66(5):625–630.
   PubMedGoogle Scholar
• Nicoletto RE, Ofner CM. Cytotoxic mechanisms of doxorubicin at clinically relevant concentrations in breast cancer cells. Cancer Chemother Pharmacol. 2022;89(3):285–311. doi:10.1007/s00280-022-04400-y.
   PubMed Web of Science ®Google Scholar
• Housman G, Byler S, Heerboth S, Lapinska K, Longacre M, Snyder N, Sarkar S. Drug resistance in cancer: an overview. Cancers (Basel). 2014;6(3):1769–1792. doi:10.3390/cancers6031769.
   PubMed Web of Science ®Google Scholar
• Gillis JS. Microarray evidence of glutaminyl cyclase gene expression in melanoma: implications for tumor antigen specific immunotherapy. J Transl Med. 2006;4(1):27. doi:10.1186/1479-5876-4-27.
   PubMedGoogle Scholar
• Jarzab B, Wiench M, Fujarewicz K, Simek K, Jarzab M, Oczko-Wojciechowska M, Wloch J, Czarniecka A, Chmielik E, Lange D, et al. Gene expression profile of papillary thyroid cancer: sources of variability and diagnostic implications. Cancer Res. 2005;65(4):1587–1597. doi:10.1158/0008-5472.CAN-04-3078.
   PubMed Web of Science ®Google Scholar
• Fluge Ø, Bruland O, Akslen LA, Lillehaug JR, Varhaug JE. Gene expression in poorly differentiated papillary thyroid carcinomas. Thyroid. 2006;16(2):161–175. doi:10.1089/thy.2006.16.161.
   PubMed Web of Science ®Google Scholar
• Griffith OL, Melck A, Jones SJ, Wiseman SM. Meta-analysis and meta-review of thyroid cancer gene expression profiling studies identifies important diagnostic biomarkers. J Clin Oncol. 2006;24(31):5043–5051. doi:10.1200/JCO.2006.06.7330.
   PubMed Web of Science ®Google Scholar
• Abdin SM, Tolba MF, Zaher DM, Omar HA. Nuclear factor-κB signaling inhibitors revert multidrug-resistance in breast cancer cells. Chem Biol Interact. 2021. 340:109450. doi:10.1016/j.cbi.2021.109450.
   PubMed Web of Science ®Google Scholar
• Mustafa YF. Synthesis, characterization, and biomedical assessment of novel bisimidazole–coumarin conjugates. Appl Nanosci. 2021;13(3):1907–1918. doi:10.1007/s13204-021-01872-x.
   Google Scholar